Eli Lilly has introduced Mounjaro in the Indian market, a novel once-weekly injectable medication designed for individuals with type 2 diabetes and those seeking weight management solutions. This new drug, approved by the Central Drugs Standard Control Organization (CDSCO), works by targeting GIP and GLP-1 receptors to enhance blood sugar regulation and promote weight loss. The efficacy of Mounjaro has been demonstrated in clinical trials, illustrating promising outcomes and highlighting its potential in managing both diabetes and obesity. The launch of this innovative treatment option signifies a significant advancement in the field of diabetes care in India, offering new hope for patients looking to better control their condition and achieve their weight management goals.